Arthritis Drug’s $1.4 Billion Promise for 4SC Hinges on Study

4SC AG said study results due by the end of next month may help the German biotechnology company secure a licensing deal for its experimental rheumatoid arthritis medicine, Vidofludimus.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.